Cibus Inc

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cibus Inc reports Q2 loss, eyes commercial transition and growth

Cibus Inc's Q2 2023 performance reflects increased expenses and a net loss, with a focus on commercial transition.
Strengths lie in the efficient Trait Machine process, optimistic market outlook, and strategic collaborations.
Challenges include financial uncertainties, regulatory complexities, and balancing R&D with commercial goals.
Opportunities encompass product expansion, technology extension, M&A potential, and favorable market regulations.

Cibus Inc transitions to commercial focus with promising trait developments

Cibus Inc is transitioning to a commercial focus with promising trait developments in major crops.
Despite a net loss in Q3 2023, the company remains optimistic about future growth opportunities.
Regulatory advancements and strategic realignment position Cibus for potential market expansion.

Cibus Inc excels in gene editing transition, eyes industry growth

Cibus Inc's Q4 performance showcased successful transition, strong market focus, and strategic financial management.
While facing challenges related to merger impacts and spending adjustments, the company remains optimistic about growth opportunities.
With a clear vision for innovation and market leadership, Cibus is poised for continued success in the gene editing agricultural sector.

Cibus Inc (CBUS) reports strong Q1 performance amidst gene editing advancements

Cibus Inc (CBUS) had a strong Q1 2024 performance with revenue exceeding expectations, driven by increased customer demand. The company is navigating challenges in market penetration and increased expenses but sees opportunities in regulatory advances and advancing their gene editing platforms.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cibus, Inc. engages in the research and development of plant traits to seed companies for royalties. It focuses on using gene editing to develop productivity traits in major agricultural crops such as Canola, Rice, Soybean, Corn and Wheat. The company was founded by Rory Riggs, Peter Beetham and Greg Gocal in 2010 and is headquartered in San Diego, CA.

Bellerophon Therapeutics

Innovative Eyewear Inc

Panbela Therapeutics Inc

Vor Biopharma

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 5 Health Care Stocks That Could Lead To Your Biggest Gains In July - Cibus (NASDAQ:CBUS), Bellerophon Therapeutics (NASDAQ:BLPH)

SAN DIEGO, June 15, 2023 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties, welcomed the passage of the Genetic Technology (Precision Breeding) Act 2023 (the “Act”) into law in the United Kingdom. The Act removes plants produced through precision breeding technologies from regulatory requirements applicable in England to the environmental release and marketing of GMOs (Genetically Modified Organisms). It is expected to enable the development and marketing of gene edited crops in England. The Act introduces a simplified regulatory system for gene edited or ‘precision bred' crops, which have been developed with targeted genetic changes that could have arisen through conventional breeding or other natural processes. The passing of the Act aligns England's regulatory path for gene editing technologies with other countries that have enacted similar legislation that regulate traits from Cibus' gene editing platform on a similar basis as traits developed using conventional breeding technologies.

Cibus Applauds the Genetic Technology (Precision Breeding) Act 2023 Passed in the United Kingdom

SAN DIEGO, June 15, 2023 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties, today announced that members of its leadership team will participate in the following upcoming investor conferences:

Cibus to Participate in Upcoming Investor Conferences

SAN DIEGO, June 07, 2023 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties, today announced that it had additional greenhouse test results demonstrating successful resistance against White Mold (Sclerotinia) in canola. This greenhouse tests showed both an enhanced and an additional mode of action from previously reported field trial results of the Cibus Sclerotinia resistance trait. Together, these two different modes of action provide an increased level of resistance against Sclerotinia than each alone.

Cibus' White Mold Resistance Trait in Canola Achieves Another Important Milestone

Cibus Class A Common Stock to commence trading on Nasdaq Capital Market on June 1, 2023 under ticker symbol “CBUS” Merger follows closing of $118.5 million private financing by Cibus Global SAN DIEGO, June 01, 2023 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties, today announced the closing of its previously announced merger with Calyxt, Inc. (“Calyxt”). In connection with, and immediately preceding, the closing of the merger, Calyxt effected the previously announced reverse stock split of Calyxt common stock at a ratio of 1-for-5.

Cibus Announces Closing of Merger with Calyxt to Create Industry Leading Precision Gene Editing and Trait Development Company

News for Cibus Inc Stock (CBUS)